Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated just now
PreprintAll rights reservedmedRxiv

Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma

  • P. R. Sudalagunta
  • F. Ionescu
  • R. R. Canevarolo
  • M. C. S. Silva1
  • D. DeAvila
  • M. B. Meads
  • X. Zhao
  • A. Perez
  • D. Drekolias
  • R. Irimia
  • S. Thapa
  • P. Patel
4 more authors
  • R. Baz
  • K. H. Shain
  • A. S. Silva1
  • A. Grajales-Cruz
  1. 1H. Lee Moffitt Cancer Center & Research Institute
Read full textPDFDOICite

Related

  1. Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
    Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg +6
    Annals of hematologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  2. Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models
    Fei Huang, Joshua J. Rusbuldt, Leopoldo Luistro +2
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.
    Michael Canonico, Parth Patel, Najla H Al Ali +15
    Blood neoplasiaPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
    Guilin Ren, Guangyu Zhou, Hao Zhou +8
    Cancer medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL
    Niranjan Khaire, Elias Jabbour, Tapan Kadia +11
    Blood neoplasiaPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@misc{sudalagunta2026venetoclaxbased,
  title = {{Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma}},
  author = {P. R. Sudalagunta and F. Ionescu and R. R. Canevarolo and M. C. S. Silva and D. DeAvila and M. B. Meads and X. Zhao and A. Perez and D. Drekolias and R. Irimia and S. Thapa and P. Patel and R. Baz and K. H. Shain and A. S. Silva and A. Grajales-Cruz},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.02.26361956},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.02.26361956v1},
}
RIS
TY  - UNPB
TI  - Venetoclax-based Therapy Improves Outcomes across the Evolving Biology of t(11;14) Multiple Myeloma
AU  - P. R. Sudalagunta
AU  - F. Ionescu
AU  - R. R. Canevarolo
AU  - M. C. S. Silva
AU  - D. DeAvila
AU  - M. B. Meads
AU  - X. Zhao
AU  - A. Perez
AU  - D. Drekolias
AU  - R. Irimia
AU  - S. Thapa
AU  - P. Patel
AU  - R. Baz
AU  - K. H. Shain
AU  - A. S. Silva
AU  - A. Grajales-Cruz
PY  - 2026
DA  - 2026/09/02
PB  - medRxiv
DO  - 10.64898/2026.09.02.26361956
UR  - https://www.medrxiv.org/content/10.64898/2026.09.02.26361956v1
ER  -